Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion

被引:16
|
作者
Gewaily, Dina [1 ]
Greenberg, Paul B. [1 ]
机构
[1] Brown Univ, Warren Alpert Med Sch, VA Med Ctr,Sect Ophthalmol, Rhode Isl Hosp,Div Ophthalmol, Providence, RI 02908 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; TRIAMCINOLONE ACETONIDE; INJECTION; ENDOPHTHALMITIS; TOXICITY; MANAGEMENT; EFFICACY; THERAPY; CRVO;
D O I
10.1002/14651858.CD007324.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Central retinal vein occlusion (CRVO) is a common retinal vascular abnormality associated with conditions such as hypertension, diabetes, glaucoma, and a wide variety of hematologic disorders. Macular edema (ME) represents an important vision-threatening complication of CRVO. There is no proven treatment; laser photocoagulation is not effective in treating cystoid macular edema secondary to CRVO. Intravitreal steroids, such as triamcinolone acetonide, have been utilized to treat macular edema stemming from a variety of etiologies and may represent a treatment option for CRVO-ME. Objectives The objective of this review was to explore the effectiveness and safety of intravitreal steroids in the treatment of CRVO-ME. Search strategy We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2008), MEDLINE (January 1950 to November 2008) and EMBASE (January 1980 to November 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 5 November 2008. For all included primary studies, we used The Science Citation Index and manually reviewed reference lists to identify other possible relevant trials. We contacted researchers in the field, currently working on a randomized controlled trial (RCT) on this topic (The Standard Care versus Corticosteroid for Retinal Vein Occlusion-SCORE study), for information on additional current, past, or unpublished trials. Selection criteria We considered RCTs that compared intravitreal steroids of any dosage/duration to observation in the treatment of CRVO-ME for inclusion in this review. We focused on studies that included individuals of any age or gender with unilateral or bilateral disease, with a minimum of six months follow up. Secondarily we considered non-randomized studies with the same criteria for description of evidence, however we did not conduct a separate electronic search for finding all non-randomized studies. Data collection and analysis We found no RCTs that met the inclusion criteria after independent and duplicate review of the search results. Main results We found no relevant RCTs and therefore performed no meta-analysis. Evidence from non-randomized studies is reported in this review. Authors' conclusions There is inadequate evidence for the use of intravitreal steroids for CRVO-ME due to a paucity of RCTs and well-designed observational studies on the topic; therefore, it is still an experimental procedure.
引用
收藏
页数:29
相关论文
共 50 条
  • [41] Intravitreal Plasmin Without Vitrectomy for Macular Edema Secondary to Branch Retinal Vein Occlusion
    Udaondo, Patricia
    Diaz-Llopis, Manuel
    Garcia-Delpech, Salvador
    Salom, David
    Romero, Francisco J.
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2011, 129 (03) : 283 - 287
  • [42] Intravitreal Pegaptanib Sodium for Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
    Udaondo, P.
    Garcia-Delpech, S.
    Salom, D.
    Bosch, F.
    Diaz-Llopis, M.
    [J]. PROCEEDINGS OF THE 7TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS, 2008, : 193 - +
  • [43] Intravitreal Bevacizumab (IVB) for Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
    Azhar, Muhammad Naeem
    Muzaffar, Waqar
    Arain, Muhammad Aamir
    Farooq, Omer
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2018, 28 (10): : 758 - 761
  • [44] Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion
    Giuffre, Chiara
    Cicinelli, Maria Vittoria
    Marchese, Alessandro
    Coppola, Michele
    Parodi, Maurizio Battaglia
    Bandello, Francesco
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (04) : 787 - 793
  • [45] Short-term prospective study of intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion
    Tsuiki, Eiko
    Suzuma, Kiyoshi
    Matsumoto, Makiko
    Kitaoka, Takashi
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [46] EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION
    Sun, Zuhua
    Zhou, Haiying
    Lin, Bing
    Jiao, Xuan
    Luo, Yingdong
    Zhang, Feng
    Tao, Shanshan
    Wu, Quan
    Ke, Zunhong
    Liu, Xiaoling
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (09): : 1723 - 1730
  • [47] Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Yuan, Alex
    Ahmad, Baseer U.
    Xu, David
    Singh, Rishi P.
    Kaiser, Peter K.
    Martin, Daniel F.
    Sears, Jonathan E.
    Schachat, Andrew P.
    Ehlers, Justis P.
    [J]. INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2014, 7 (01) : 86 - 91
  • [48] Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion
    Topcic, Ivana Gardasevic
    Sustar, Maja
    Brecelj, Jelka
    Hawlina, Marko
    Mekjavic, Polona Jaki
    [J]. DOCUMENTA OPHTHALMOLOGICA, 2014, 129 (01) : 27 - 38
  • [49] Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion
    Çekiç, O
    Chang, S
    Tseng, JJ
    Barile, GR
    Del Priore, LV
    Weissman, H
    Schiff, WM
    Ober, MD
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (07): : 851 - 855
  • [50] Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Alex Yuan
    Baseer U.Ahmad
    David Xu
    Rishi P.Singh
    Peter K.Kaiser
    Daniel F.Martin
    Jonathan E.Sears
    Andrew P.Schachat
    Justis P.Ehlers
    [J]. International Journal of Ophthalmology, 2014, 7 (01) : 86 - 91